Online citations, reference lists, and bibliographies.
← Back to Search

Expression Of Cytokeratin 5/6 In Epithelial Neoplasms: An Immunohistochemical Study Of 509 Cases

P. Chu, L. Weiss
Published 2002 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Cytokeratin 5/6 (CK 5/6) immunoreactivity has been observed in the vast majority of cases of malignant mesothelioma but only rarely in pulmonary adenocarcinomas. Thus, CK 5/6 has been used to distinguish malignant mesothelioma from pulmonary adenocarcinoma. However, the utility of CK 5/6 in distinguishing pleural malignant mesothelioma from pleural metastases from nonpulmonary adenocarcinoma, as well as peritoneal malignant mesothelioma from peritoneal metastatic adenocarcinoma, has not yet been adequately addressed because the tissue expression of CK 5/6 in nonpulmonary neoplasms has not been well defined. We have studied the CK 5/6 expression in 509 cases of various epithelial tumors by immunohistochemistry. We found that the vast majority of cases of squamous cell carcinoma, basal cell carcinoma, thymoma, salivary gland tumor, and biphasic malignant mesothelioma were positive for CK 5/6. In addition, CK 5/6 immunoreactivity was detected in 15 of 24 cases (62%) of transitional cell carcinoma, in 5 of 10 cases (50%) of endometrial adenocarcinoma, in about one third of cases of pancreatic adenocarcinoma (38%) and breast adenocarcinoma (31%), and in one quarter of cases of ovarian adenocarcinomas (25%). Our study confirms the diagnostic utility of CK 5/6 immunohistochemistry in distinguishing biphasic mesothelioma from pulmonary adenocarcinoma but raises caution about its use for the differential diagnosis of pleural or peritoneal malignant mesothelioma versus pleural or peritoneal metastatic nonpulmonary adenocarcinoma, because many types of nonpulmonary adenocarcinomas may be positive for CK 5/6.
This paper references
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1007/BF02890064
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas
R. Moll (1989)
10.1016/s0147-0272(88)80005-9
Asbestos-related malignancy.
J. Talcott (1988)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
C. Moran (2000)
10.1097/00000478-199712000-00002
The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
N. Ordóñez (1997)
10.1016/0091-7435(77)90025-1
Epidemiology of mesothelioma from estimated incidence.
J. C. Mcdonald (1977)
Cytokeratin 5/6 (CK 5/6) is an effective substitute for keratin 903 (K 903) in the differentiation of benign (BG) from malignant glands (MG) in prostate needle biopsies [abstract
NA Abrahams (2001)
Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations.
D. Cooper (1985)
10.1046/j.1365-2559.2001.01105.x
Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours
P. Chu (2001)
10.1016/S0046-8177(98)90227-1
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
10.1046/j.1365-2559.2000.00981.x
Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
R. Attanoos (2000)
10.1093/AJCP/95.3.322
The use of monoclonal antibody 44-3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma.
D. Spagnolo (1991)
10.1046/j.1365-2559.1998.00349.x
E‐cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
Leers (1998)
Advances in immunohistochemistry: impact on surgical pathology practice.
Chan Jk (2000)
10.1097/00129039-200206000-00009
Cytokeratin 5/6 Immunostaining in Hepatobiliary and Pancreatic Neoplasms
Dmitry M Vlasoff (2002)
The value of the antibodies 44 –3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma
NG Ordóñez (1997)
[Peritoneal mesothelioma].
R. Osieka (1980)
10.1038/modpathol.3880397
Angiogenic Polypoid Proliferation Adjacent to Ileal Carcinoid Tumors: A Nonspecific Finding Related to Mucosal Prolapse
N. Abrahams (2001)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
Keratin immunohistochemistry: update of applications and pitfalls.
M. Miettinen (1993)



This paper is referenced by
10.1700/1660.18182
Expression of Thrombomodulin, Calretinin, Cytokeratin 5/6, D2–40 and WT-1 in a Series of Primary Carcinomas of the Lung: An Immunohistochemical Study in Comparison with Epithelioid Pleural Mesothelioma
C. Comin (2014)
10.1111/j.1440-1827.2009.02480.x
Thyroid‐like low‐grade nasopharyngeal papillary adenocarcinoma: Report of two cases
C. Ohe (2010)
10.1016/j.humpath.2017.03.020
Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
E. T. Taube (2017)
10.1097/00000478-200208000-00002
Hepatocyte Antigen as a Marker of Hepatocellular Carcinoma: An Immunohistochemical Comparison to Carcinoembryonic Antigen, CD10, and Alpha-Fetoprotein
P. Chu (2002)
10.1309/D744C4NM15J3B00D
Vascular endothelial growth factor expression in the basal subtype of breast carcinoma.
A. Ribeiro-Silva (2006)
10.1016/J.RMEDC.2009.10.002
Primary pulmonary combined scar carcinoma composed of adenocarcinoma, squamous cell carcinoma, and small cell carcinoma: An autopsy case and literature review
T. Terada (2010)
10.1136/jcp.2005.029652
My approach to the diagnosis of mesothelial lesions
K. Butnor (2006)
10.5146/tjpath.2010.01023
The Role of D2-40, and Podoplanin in Differentiating Mesotheliomas from Primary Adenocarcinomas of the Lung and Metastatic Carcinomas of the Pleura D2-40 ve Podoplanin'in Mezotelyomalarin Akciğerin Primer Adenokarsinomlari ve Plevranin Metastatik Karsinomlarindan Ayrimindaki Rolü
Seda Gun (2010)
10.2353/jmoldx.2010.090197
Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site.
B. Centeno (2010)
10.1097/PAS.0000000000000254
Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology: Report From the International Society of Urological Pathology Consensus Conference
M. Amin (2014)
10.1016/S0242-6498(06)70658-7
[Benign salivary gland-type tumors of the bronchus: expression of high molecular weight cytokeratins].
F. Méjean-Lebreton (2006)
10.1080/00313020701230849
Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for management
S. Pinder (2007)
Immunohistochemistry: A Revolutionary Technique in Laboratory Medicine
Jude Ogechukwu Okoye (2015)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
10.1016/J.THORSURG.2004.06.007
Pathology of mesothelioma.
J. M. Corson (2004)
10.1111/j.1600-0560.2008.01083.x
Adenosquamous carcinoma: a report of nine cases with p63 and cytokeratin 5/6 staining
C. Ko (2009)
Zane Simtniece PROGNOSTIC FACTORS OF SURGICALLY TREATED PANCREATIC CANCER Summary of the Doctoral Thesis for obtaining the degree of a Doctor of Medicine Speciality – Pathology
Zane Simtniece (2015)
10.1111/cas.13120
High KRT8 expression promotes tumor progression and metastasis of gastric cancer
J. Fang (2017)
10.1097/00125480-200209000-00002
Taking Advantage of Basic Research: p63 Is a Reliable Myoepithelial and Stem Cell Marker
J. S. Reis-Filho (2002)
10.1111/apm.12828
Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression
S. Andreasen (2018)
10.1002/hed.25411
Induction of squamous cell carcinoma after MAP3K8 overexpression in murine salivry gland epithelial cells
Jun-Han Lee (2019)
10.1097/PAI.0b013e3181ecaf1c
Can We Tell the Site of Origin of Metastatic Squamous Cell Carcinoma? An Immunohistochemical Tissue Microarray Study of 194 Cases
T. C. Pereira (2011)
10.1016/j.gcb.2010.07.016
Primary peritoneal mesothelioma: case series and literature review.
H. Sharma (2011)
10.1016/B978-1-4557-2865-7.00094-1
Carcinoma of Unknown Primary
G. Varadhachary (2001)
10.1159/000325601
CK5/6 in Effusions
A. Dejmek (2008)
10.1136/jclinpath-2012-201140
Immunohistochemistry in the era of personalised medicine
C. McCourt (2012)
Role of Vascular Endothelial Growth Factor Expression in Subtyping of Breast Carcinoma *
A. R. Shalaby (2012)
10.1017/CBO9781316167366.007
Tumors of the genitourinary system
P. Chu (2014)
10.1097/01.MP.0000039571.02827.CE
Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry
F. Hsu (2002)
10.1354/vp.08-VP-0097-T-FL
Myocardial Adenomatoid Tumor in Eight Cattle: Evidence for Mesothelial Origin of Bovine Myocardial Epithelial Inclusions
M. Tursi (2009)
10.1043/1543-2165(2008)132[1062:IOPAPN]2.0.CO;2
Immunohistochemistry of pulmonary and pleural neoplasia.
M. Beasley (2008)
10.1309/8FCHQ3VPBWM7B5X9
Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
R. Barnetson (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar